6-arylamino pyridone carboxamide as MEK inhibitors

A compound of formula I

• wherein
• represents X—Y═W or W—Y═X,
• X independently represent N, O, or S;
• W is CR2, N, or S;
• Y is N or CR1;
• and
• R1 is selected from the group consisting of H and C1-C6 alkyl;
• wherein each alkyl is optionally substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxy, amino, C1-C6 alkylamino, diC1-C6 alkylamino, and C1-C6 heterocyclyl;
• R2 is selected from the group consisting of H and C1-C10 alkyl, where each alkyl is unsubstituted or substituted with 1-3 substituents selected independently from halogen, hydroxyl, and C1-C4 alkyl;
• R3 is selected from the group consisting of H, C1-C10 alkyl, C1-C10 alkoxy, C3-C10 cycloalkyl, C3-C10 cycloalkylalkyl, where each alkyl, alkoxy, and cycloalkyl is unsubstituted or substituted with 1-3 substituents selected independently from the group consisting of halogen, hydroxyl, C1-C4 alkyl, and C1-C4 alkoxy;
• R3′ is selected from the group consisting of H and C1-C6 alkyl;
• R4, R5, R6, R7 and R8 are independently selected from the group consisting of H, halogen, SR9, and OR9;
• R9 is selected from the group consisting of hydrogen and C1-C10 alkyl;
• R13 is selected from the groups consisting of H and C1-C6 alkyl;
• and
• R14 is selected from the groups consisting of H and C1-C6 alkyl;
• or a pharmaceutically acceptable salt, solvate, poly-morph, or tautomer thereof.